CK Life Sciences completed a $25m investment in TransCode Therapeutics.

CK Life Sciences, a company which is engaged in healthcare research and development, completed a $25m investment in TransCode Therapeutics, a Boston-based biotechnology company focused on oncology. "I am very honoured to deepen my commitment and lead TransCode's transformation into a one-of-a-kind leading oncology company at this critical time. We are grateful for CK Life Sciences' investment and their support of our miRNA candidate, TTX-MC138, as we now have the funding in place to fully execute our upcoming TTX-MC138 Phase 2," Dr. Philippe Calais, TransCode Therapeutics CEO.